SCHEMBL4152933

SCHEMBL4152933

CN(C)CC(=O)Nc1ccc(CCN)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
HRH3 Q9Y5N1 1/20 0.53
ALDH1A1 P00352 5/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TAAR1 Q96RJ0 1/20 0.50
POLB P06746 2/20 0.49
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALOX15 P16050 1/20 0.47
NFKB1 P19838 1/20 0.47
MAPK1 P28482 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
MCL1 Q07820 1/20 0.47
HPGD P15428 3/20 0.47
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12953853 0.87 MAPT (0.62) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL20245304 0.85 POLB (0.58) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL1409656 0.83 MAPT (0.66) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL8251271 0.81 KMT2A (0.63) MAPTALDH1A1L3MBTL1TAAR1POLB
SCHEMBL5775605 0.81 MAPT (0.59) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL4152931 0.81 MAPT (0.59) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL26710499 0.80 HDAC1 (0.49) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL16619432 0.78 ACHE (0.54) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL10916539 0.78 MAPT (0.63) MAPTHRH3ALDH1A1L3MBTL1TAAR1
SCHEMBL764662 0.78 POLB (0.68) MAPTALDH1A1L3MBTL1TAAR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 MAPT 119/4885HRH3 2297/4885ALDH1A1 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.